Ed van RijswijkNovel first-in-class antibodies block inflammation pathway in autoimmune diseases
Researchers at UMC Utrecht have developed two novel antibodies that specifically target the high-affinity IgG receptor FcγRI, offering a potential therapeutic approach for autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and immune thrombocytopenia. The antibodies, designated C01 and C04, effectively block immune complex binding without triggering receptor activation, addressing a key limitation of previous […]
